Tafamidis: A Game Changer in Transthyretin Cardiomyopathy? A Systematic Review of Efficacy and Safety

被引：0
|
作者：
Hussain, Bilal
Hamza, Mohammad
Sattar, Yasar
Patel, Bansari
Song, David
Patel, Neel N.
Duhan, Sanchit
Cheema, Mustafa Sajjad
Naeem, Minahil
Waqar, Hafiza Hareem
Lactana, Sharaad
Alraies, M. Chadi C.
机构：
来源：
CIRCULATION | 2023年 / 148卷
关键词：
Amyloidosis; Mortality; Heart Failure; Echocardiography;
D O I：
10.1161/circ.148.suppl_1.16556
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A16556
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Updated Evaluation of the Safety, Efficacy and Tolerability of Tafamidis in the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy
    de Campos, Catarina Falcao
    Conceicao, Isabel
    DRUG HEALTHCARE AND PATIENT SAFETY, 2023, 15 : 51 - 62
  • [42] Outcomes of Octogenarian Patients Treated with Tafamidis for Transthyretin Amyloid Cardiomyopathy
    Sarkar, Abdullah
    Sanchez-Nadales, Alejandro
    Kunutsor, Setor K.
    Hanna, Mazen A.
    Asher, Craig R.
    Wolinsky, David G.
    AMERICAN JOURNAL OF CARDIOLOGY, 2024, 214 : 144 - 148
  • [43] Efficacy of Tafamidis by Baseline 6-minute Walk Test Distance in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT)
    Maurer, Mathew S.
    Adler, Eric
    Gundapaneni, Balarama
    Sultan, Marla B.
    Rapezzi, Claudio
    JOURNAL OF CARDIAC FAILURE, 2020, 26 (10) : S10 - S10
  • [44] Tafamidis for transthyretin amyloid cardiomyopathy: the solution or just the beginning of the end?
    Falk, Rodney H.
    EUROPEAN HEART JOURNAL, 2019, 40 (12) : 1009 - 1012
  • [45] Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Cardiomyopathy: A Case Report
    Fujita, Teppei
    Inomata, Takayuki
    Kaida, Toyoji
    Iida, Yuichirou
    Ikeda, Yuki
    Nabeta, Takeru
    Ishii, Shunsuke
    Maekawa, Emi
    Naruke, Takashi
    Koitabashi, Toshimi
    Kitamura, Eiji
    Sekijima, Yoshiki
    Ako, Junya
    CARDIOLOGY, 2017, 137 (02) : 74 - 77
  • [46] Tafamidis Should Be Accessible for All Patients With Transthyretin Amyloid Cardiomyopathy
    Psotka, Mitchell A.
    JACC-HEART FAILURE, 2021, 9 (02) : 124 - 126
  • [47] Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy
    Kazi, Dhruv S.
    Bellows, Brandon K.
    Baron, Suzanne J.
    Shen, Changyu
    Cohen, David J.
    Spertus, John A.
    Yeh, Robert W.
    Arnold, Suzanne V.
    Sperry, Brett W.
    Maurer, Mathew S.
    Shah, Sanjiv J.
    CIRCULATION, 2020, 141 (15) : 1214 - 1224
  • [48] Change in echocardiography in patients with transthyretin amyloid cardiomyopathy with tafamidis treatment
    Morioka, M.
    Takashio, S.
    Fujiyama, H.
    Oike, F.
    Hanatani, S.
    Usuku, H.
    Yamamoto, E.
    Matsushita, K.
    Tsujita, K.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1764 - 1764
  • [49] Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review
    Bishev, Daniel
    Fabara, Stephanie
    Loseke, Isaac
    Alok, Akankcha
    Al-Ani, Hashim
    Bazikian, Yvette
    HEART LUNG AND CIRCULATION, 2023, 32 (09): : 1049 - 1056
  • [50] Improvement in Measures of Disease Progression With Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT)
    Hanna, Mazen A.
    Fine, Nowell
    Gundapaneni, Balarama
    Sultan, Marla B.
    Witteles, Ronald
    CIRCULATION, 2021, 144
12345